注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
PMV Pharmaceuticals Inc是一家致力于发现和开发靶向p53的小分子以及肿瘤未知疗法的精密肿瘤学公司。该公司的主要候选产品PC14586是一种旨在有效和选择性地纠正由特定p53突变Y220C引起的p53错误折叠,同时保留野生型p53的口服小分子。PC14586旨在通过占据氨基酸位置220的酪氨酸至半胱氨酸突变产生的缝隙来恢复野生型构象。该公司还利用其精准肿瘤学平台开发了一种口服小分子候选产品,这种候选产品在结构上纠正其他p53热点突变以恢复其野生型功能,并针对某些野生型p53功能沉默的癌症。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Scott W. Lowe | - | - | Chairman of Scientific Advisory Board |
David H. Mack | 62 | 2013 | Co-Founder, CEO, President & Director |
Arnold J. Levine | 84 | 2013 | Co-Founder, Director & Member of Scientific Advisory Board |
Frank P. McCormick | 74 | - | Member of Scientific Advisory Board |
Karen H. Vousden | 65 | - | Member of Scientific Advisory Board |
Charles M. Baum | 66 | 2021 | Independent Director |
Michael E. Jung | - | - | Member of Scientific Advisory Board |
Richard A. Heyman | 67 | 2020 | Independent Chairman of the Board of Directors & Member of Scientific Advisory Board |
Charles L. Sawyers | 65 | - | Member of scientific Advisory Board |
Kirsten Flowers | 49 | 2022 | Independent Director |
Carol G. Gallagher | 59 | 2022 | Independent Director |
Guillermina Lozano | - | 2021 | Member of Scientific Advisory Board |
Laurie D. Stelzer | 56 | 2020 | Independent Director |
Thomas E. Shenk | 77 | 2013 | Co-Founder & Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核